Wegovy Pills vs Injections: Effectiveness, Side Effects, and What You Need to Know

FDA Approves First Oral GLP-1 Pill for Weight Loss

Introduction to Wegovy’s Approval

In December 2025, the U.S. Food and Drug Administration (FDA) granted approval for an oral pill form of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist aimed at weight loss. Previously, Wegovy was exclusively available as a weekly self-injection.

Differences Between Wegovy Pill and Injection

The primary distinction between the Wegovy pill and its injectable counterpart lies in their administration methods and frequency of use. While both formulations exhibit similar side effects, there are subtle differences that users should consider.

Expert Insights on Wegovy

Medical News Today consulted three obesity medicine specialists to delve deeper into the implications of the Wegovy pill. They discussed why this approval is deemed a “game-changer,” highlighted the differences from the injectable version, and offered guidance on selecting the appropriate form of Wegovy for individual needs.